Frontiers in Cardiovascular Medicine

APRIL 24, 2024

The early detection of plaques by circulating biomarkers is highly clinically relevant to prevent the occurrence of major complications such as stroke or heart attacks. BackgroundAtherosclerosis is a widespread disorder of the cardiovascular system.

Plaque 52

Plaque Circulation Biomarkers Stenosis 52

DAIC

JUNE 4, 2024

fold higher risk for major adverse cardiac events (MACE) Caristo's AI-Risk model, CaRi-Heart Risk Score, outperformed other scores in routine clinical use for prediction of cardiac mortality, and when presented to clinicians, resulted in changes of management decision in 45% of the patients. fold higher risk for cardiac mortality and 5.5-fold

Technology 116

Technology Heart Attack Heart attacks Coronary Artery Disease 116

DAIC

JANUARY 23, 2024

3 Patients with ASCVD are at a higher risk for major adverse cardiovascular events (MACE) including heart attack or myocardial infarction (MI), stroke, and cardiovascular (CV) death.4 milligrams per liter (mg/L) are linked to increased risk of heart attacks or risk of a repeat heart attack.23

Cardiovascular Disease 111

Cardiovascular Disease Heart Attack Heart attacks Coronary Artery Disease 111

DAIC

DECEMBER 13, 2023

MILLER, PHD, LED THE DEVELOPMENT OF A NEW "ATHEROSCLEROSIS ATLAS" THAT DETAILS, AT THE LEVEL OF INDIVIDUAL CELLS, CRITICAL PROCESSES RESPONSIBLE FOR FORMING THE HARMFUL PLAQUE BUILDUP THAT CAUSES HEART ATTACKS, STROKES AND CORONARY ARTERY DISEASE. When they break loose, they can be deadly, triggering strokes and heart attacks.

Heart Attack 105

Heart Attack Heart attacks Atherosclerosis Stroke 105

DAIC

APRIL 9, 2024

Although they had no symptoms of heart failure or blockages in arteries carrying blood to the heart, they all had structural heart disease or abnormal cardiac biomarkers that classified them as having “pre-heart failure,” putting them at high risk for developing overt symptoms of the diagnosis.

Heart Failure 52

Heart Failure Diabetes Cardiomyopathy Exercise 52

Dr. Paddy Barrett

SEPTEMBER 19, 2023

A therapy that has been proven repeatedly to reduce the probability of heart attacks and strokes in multiple double-blind randomised controlled studies 1. Additionally, access to cholesterol synthesis biomarker testing, including desmosterol and lathosterol levels, can be challenging to obtain. J Lipid Res.

Dementia 52

Dementia Cholesterol Biomarkers Circulation 52

DAIC

MARCH 7, 2024

Patients treated with CardiAMP cell therapy saw an almost 5% lower rate of heart death equivalents at up to two years compared to control patients treated with heart failure medication alone (8.3% vs. 13.2%, respectively).

Heart Failure 105

Heart Failure Biomarkers CMS Reimbursement 105